Patient-First Model: High Tech Meets High Touch for Individuals with Rare Disorders
Donovan Quill, President and CEO, Optime Care Industry experts state that orphan drugs will be a major trend to watch in the years ahead, accounting for almost 40% of the Food and Drug Administration approvals this year. This market has become more competitive in the past few years,… Read More »Patient-First Model: High Tech Meets High Touch for Individuals with Rare Disorders